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Abstract 
Background: Evidence for effective treatment options for orthostatic hypotension (OH) in Parkinson`s disease 
(PD) is scarce. Elevation of cholinergic tone with Pyridostigmine bromide has been reported as a way to improve 
blood pressure (bp) regulation in neurogenic hypotension without causing supine hypertension.   
Methods: Double-centre, double blind, randomized, active-control, crossover, phase II non-inferiority trial of 
Pyridostigmine bromide for OH in PD (clinicaltrials.gov NCT01993680). Patients with confirmed OH were 
randomized to 14 days 3x60mg/d Pyridostigmine bromide or 1x0.2mg/d Fludrocortisone before crossover. 
Outcome was measured by peripheral and central bp monitoring during Schellong manoeuvre and 
questionnaires.  
Results: Thirteen participants were enrolled between 04/2013 and 04/2015 with 9 participants completing each 
trial arm. Repeated-measures comparison showed a significant 37% improvement with Fludrocortisone for the 
primary outcome diastolic bp drop on orthostatic challenge (baseline 22.9±13.6 vs. Pyridostigmine bromide 
22.1±17.0 vs. Fludrocortisone 14.0±12.6 mmHg; p=0.04), while Pyridostigmine bromide had no effect. 
Fludrocortisone caused an 11% peripheral systolic supine (baseline 128.4±12.8 vs. Pyridostigmine bromide 
130.4±18.3 vs. Fludrocortisone 143.2±10.1; p=0.01) but no central mean arterial supine bp rise (baseline 
107.2±7.8 vs. Pyridostigmine bromide 97.0±12.0 vs. Fludrocortisone 107.3±6.3; p=0.047). Subjective OH 
severity, motor score and quality of life remained unchanged by both study interventions.  
Conclusions: Pyridostigmine bromide is inferior to Fludrocortisone in the treatment of OH in PD. This trial 
provides first objective evidence of efficacy of 0.2mg/d Fludrocortisone for OH in PD, causing minor peripheral 
but no central supine hypertension. In addition to peripheral bp, future trials should include central bp 
measurements, known to correlate more closely with cardiovascular risk. 
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Introduction 
 
The disease burden by autonomic dysfunction in Parkinson`s disease (PD) is increasingly recognized. 
Orthostatic hypotension (OH) is reported to have an incidence of around 30% in PD (1) and a particular high 
influence on quality of life (2), while there is still only Class III evidence for therapeutic interventions (3). 
Current treatment strategies anchor at behavioral adaptations, increasing overall blood pressure (bp) by elevation 
of plasma volume (increased salt or volume intake, erythropoietin, desmopressin, fludrocortisone) or 
administering vasoactive agents (etilefrine, midodrine, octreotide, droxidopa) (4). Until now, however, all of 
these interventions for OH in PD are viewed as investigational (5), reflecting the lack of randomized controlled 
trials.  
In addition to decreased cardiovascular sympathetic innervation (6), impaired baroreflex function is a major 
factor for OH in PD (7). Elevation of cholinergic tone by pyridostigmine bromide (PB) has been suggested to be 
an effective therapeutic option for OH by strengthen both limbs of the baroreflex without causing supine 
hypertension (8). Results from a trial in a cohort of patients with neurogenic OH were promising (8). We 
therefore aimed at studying the effect of PB on OH in a PD cohort. A non-inferiority design was chosen with 
fludrocortisone (FC), a synthetic mineralocorticoid widely available and used, as an active comparator. Open-
label studies in small samples have suggested that FC improves OH in multiple system atrophy (9) and in 
levodopa induced OH (10), while the only randomized controlled trial in PD showed an effect on subjective OH 
symptom severity but not blood pressure measurements (11).  
 
 
Methods 
 
This double-centre, double blind, randomized, active-control, crossover, phase II non-inferiority trial was 
conducted in accordance with national and international law and good clinical practice. It was registered locally 
and internationally (clinicaltrials.gov NCT01993680). The study protocol was approved by the Zurich cantonal 
ethics committee and the national medical regulatory body Swissmedic. All participants provided written 
informed consent for participation prior to inclusion. The study was designed with diastolic bp drop on 
Schellong maneuver (mmHg) as the primary outcome measure. Power calculations were based on previously 
reported effect sizes for PB in neurogenic OH (8) with a non-inferiority margin M of 50%. For an effect size of 
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2.45 and a calculated error probability of α = 0.05 (resulting power (1-β) = 0.95), an overall sample size of n=10 
participants was calculated to prove non-inferiority (critical t 1.86; actual power 0.97) – to increase power, we 
aimed at n=18. 
 
Participant Selection 
PD patients with a clinical diagnosis of PD diagnosed according to UK Brain bank criteria,  50-80 years old, 
Hoehn & Yahr stages 2 and 3, suffering from symptomatic, established OH (≥20 mmHg drop systolic or 
10mmHg diastolic peripheral bp within 3 minutes of standing (12)) on routine follow-up were recruited from the 
outpatient clinics of participating centers. Patients on medication influencing bp regulation (antihypertensive 
drugs, mirtazapine, sertraline, paroxetine, fluoxetine, venlafaxine, trazodone, anticholinergics, etc.), depolarizing 
muscle relaxants, with systemic disease (diabetes, viral or fungal infection, renal or kidney failure, malignancy), 
history of gastrointestinal disease or surgery, pathological under- or overweight and conditions interfering with 
compliance were excluded. Furthermore, patients presenting with signs for cerebellar involvement or other 
clinical or imaging features suggestive of multiple system atrophy (MSA) were not included. Participants were 
not allowed to change dopaminergic medication and physical anti-hypotension measures throughout the study. 
 
Trial design and procedures 
Study visits were conducted at the beginning and end of both trial arms of 14 days duration - 21 days of washout 
were kept before crossover, which deemed sufficient in the light of a biological half-life of 36 hours for FC and 
1.5 hours for PB directly before the first and directly after the final dose of trial medication. Trial arms had 14 
days duration and 21 days of washout before crossover, with the biological half-life being 36 (FC), respective 
1.5 hours (PB). All study visits included the same procedures and were conducted in the same clinical trial suite 
at ambient room temperature from 9 AM in the morning after an overnight fast. Investigations were performed 
after a minimum of 20min supine rest at 30° head elevation. Non-invasive central bp measurements were 
performed using pulse wave analysis by applanation tonometry (13) (SphygmoCor; AtCor Medical Pty., Sydney, 
Australia) – measurements with an operator index <80% were excluded. Cardiovascular monitoring was 
recorded continuously during Schellong manoeuvre (Nihon Kohden, Cham, Switzerland; 10min supine, 10min 
standing). Motor (UPDRS III), cognitive (Montreal Cognitive Assessment (MoCA) and additional domains 
(Hospital Anxiety and Depression Scale, Zurich autonomic questionnaire, OH symptom assessment (OHSA) 
scale (14) and quality of life) assessments were recorded in a standardized way. Home bp measurements in 
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sitting position consisted of repeat automated morning and evening measurements (WatchBPhome, microlife, 
Widnau, Switzerland) for 7 days before study visits.  
Study medication was prepared in identical capsules by the Cantonal Pharmacy of the Canton of Zurich, which 
also performed independent randomization. Study medication was kept at 4°C by participants and was started at 
3x30mg/d (PB) and 1x0.1mg (FC)  + 2x placebo/d for 3 days before dose increment to 3x60mg/d and 1x0.2mg/d 
+ 2x placebo/d. Compliance was monitored by drug calendars and collection of empty medication packaging.  
 
Data analysis 
All data are expressed as means and standard deviations. Mixed linear model statistics were used for repeated 
measures comparison. Post-hoc analysis (LSD) was performed in case of significant differences between groups. 
A two-tailed p value of 0.05 was considered significant. Statistical analysis was performed using SPSS 22.0 
(IBM, Armonk, NY). After an interim analysis of the primary outcome measure after the ninth completed data 
set (subject 13) showing futility of the primary outcome measure for PB, the trial was terminated and data 
analyzed as intention to treat. 
 
 
Results 
 
Thirteen participants were enrolled between 04/2013 and 04/2015 – for clinical characteristics see Table 1. 
Before the final study visit, two subjects withdrew consent due to strenuous study procedures, one was implanted 
with electrodes for deep brain stimulation, and one dropped out due to a non-study related accident. Data sets 
were included if trial arms were completed. Each trial arm was fully completed by 9 participants and medication 
compliance was 99%. The pre-defined non-inferiority margin M was missed and non-inferiority rejected.  
Outcome variables of the intention-to treat analysis are displayed in Table 2 and Figure 1. FC improved the 
primary outcome measure diastolic bp drop on Schellong maneuver by 37% (p=0.016), as well as minimal mean 
arterial bp standing by 15% (p=0.02), whereas PB treatment had no significant effect (Figure 1A, B). Subjective 
symptom severity was not changed by any intervention (Figure 1E) and did not correlate with changes in bp drop 
on Schellong (ns). Peripheral systolic bp supine (Figure 1C) and systolic 7d home bp measurement sitting were 
increased by 11% after FC (p=0.004) but not PB treatment. Central mean supine bp was lowered by 9% by PB 
(p=0.03) but remained unchanged after FC treatment (Figure 1D). Neither drug had any influence on motor, 
cognitive and neuropsychiatric measure or quality of life. Stool consistency was significantly softened with PB 
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treatment (p=0.015), while neither treatment had an influence on the subjective severity of other autonomic 
symptoms. While PB lowered Sodium levels (p=0.009), Potassium levels were unchanged in both trial arms 
(Figure 1F, G). 
 
Transient, mild adverse events were reported during PB (dizziness, n=1; mouth dryness, n=1; transient increase 
of motor off phase n=1) and FC treatment (leg oedema, n=1) without leading to dose adjustment or drop-out.  
There was a weak positive correlation between motor and subjective OH symptoms among participants (Figure 1 
H; r2=0.38, p=0.03). 
 
 
Discussion 
 
Futility of Pyridostigmine bromide for OH in PD 
OH is classically defined by a drop of more than 20 mmHg in systolic or 10mmHg in diastolic peripheral bp 
within 3 minutes of standing (12). Recently this has been challenged in PD, as a mean arterial bp (MBP) 
<75mmHg upon standing has been found to correlate better with OH symptoms in this patient population PD 
(15). In the present study, PB failed to display a positive effect for both OH definitions as well as for subjective 
severity of OH symptoms in PD patients. While 55% of patients had a net improvement of diastolic bp drop with 
PB (100% for FC, p=0.08), the overall mean effect size was negligible and did not reach the pre-set non-
inferiority margin M of 50%. Thus, in our homogeneous PD cohort, we could not reproduce the positive effect 
of PB on OH, as shown for a single dose of 60mg in a mixed cohort of patients with neurogenic OH (8) - follow-
up studies of the initial report did not include PD patients (16,17). Possible explanations for this discrepancy 
could be either insufficient dosing or age- and disease-inherent factors. Previous studies have reported an effect 
of 30mg (18), 120mg (19) and 180mg (20) of PB on autonomic nervous system activity in healthy controls. 
Although patients in this study received having received 180mg PB per day, it cannot be excluded that this dose 
was insufficient for elevation of cholinergic tone in this population. On the other hand, the significant subjective 
softening of stool consistency and increased heart rate change on Schellong maneuver by PB suggests a 
clinically relevant effect on the autonomic nervous system. Alternatively, different OH disease mechanisms 
might influence the effect of PB on the baroreflex. The lesion site leading to OH is central and preganglionic in 
MSA, whereas it is peripheral and postganglionic in pure autonomic failure and PD (21). So far no difference in 
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baroreflex testing has been reported between MSA and PD (22), suggesting that further studies into the exact 
pathophysiological mechanism of baroreflex dysfunction in these etiologies are warranted.  
Our results indicate that a reasonable therapeutic effect on OH in PD might not be achievable with PB. 
Furthermore, the finding of hyponatremia is an additional caveat for its long-term application in PD, although 
the exact mechanism underlying this phenomenon remains elusive.  
 
Beneficial effect of Fludrocortisone  
In contrast, our data provide the first evidence for a significant improvement on both diastolic bp drop on 
orthostatic challenge (-37%) and MBP standing (+15%) by 0,2mg FC per day in PD. As MBP and diastolic bp 
have been shown to correlate closer with symptomatic OH than systolic bp (15), we consider OH therapy with 
FC successful. So far a significant effect has only been shown in cohorts of diabetic OH and Shy-Drager 
syndrome, i.e. MSA (9,23). In the single previous trial of FC for OH in PD, 0.1mg FC per day only improved 
subjective symptoms but did neither change bp drop on orthostatic challenge nor supine systolic bp (11). 
Together with our observations this supports a dose-dependent effect of FC on bp regulation. The fact that this 
positive effect with 0.2mg FC per day on objective bp regulation was not reflected by significant changes of 
subjective OH symptom perception might be either due to the limited sample size, low sensitivity of the OHSA 
score or a possible dissociation of subjective vs. objective OH symptoms in this population (24).  
 
Treatment effects on central blood pressure 
As expected, 0.2mg FC per day caused an overall increase of peripheral bp levels – systolic bp in sitting and 
supine position was raised by 11%. According to suggested criteria, this constitutes supine hypertension (15), 
quoted to be the most relevant side effect of FC treatment (4,15). Although frequently quoted, there is no clear 
definition of supine hypertension, leading to different cut-off values applied to study data in the literature 
(15,25). Our finding of unchanged central bp with FC treatment however sheds light on another, novel aspect in 
the interpretation of supine hypertension in PD. The elastic properties of the arterial system and its branches 
cause the central bp to be amplified in the periphery and while the bp in the central arteries directly governs the 
load on the heart, this is not directly reflected by peripheral bp (26). There is compelling empirical evidence 
showing that central bp is superior in predicting cardiovascular disease risk in comparison to peripheral bp 
(26,27). To our knowledge, central bp has not been reported in PD patients before and its regulation and effect 
are to be described (11,16,25). Although further studies into central bp in PD therefore seem warranted, the 
finding of unchanged central bp under FC treatment might indicate a more favorable side effect profile with this 
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treatment than anticipated. Similarly and In contrast to previous reports, we did not observe any electrolyte 
disturbances and in particular hypokalemia with FC use.  
 
Limitations and Conclusion 
We acknowledge the number of participants and dropout rate in this trial as a weakness that warrants replication. 
Future trials with similarly strict in- and exclusion criteria will most likely need a multi-center approach (25), as 
recruitment was more difficult than anticipated. Although we excluded alternative pharmacological influence on 
bp, dopaminergic medication of course influenced bp regulation (28). However, measurements in the OFF state 
were deemed unfeasible and we think that measurements in the ON state more closely resemble clinical reality. 
Independent of this it is important that pharmacological therapy of OH should always be preceded by the 
exhaustion of non-pharmacological measures. 
This trial, however, provides first evidence for the efficacy of 0.2mg/d FC for OH in PD, which is a confirmation 
of frequent clinical practice. The observed effect size with FC treatment is of note compared to recent much 
larger trials for OH in PD that did not show a persistent benefit on bp regulation (25). We also show first 
evidence that supine hypertension in the periphery might not reflect central bp changes in PD. Additional studies 
are needed to clarify the significance of central bp and supine hypertension in the cardiovascular risk assessment 
in PD.  
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Figure and Table captions: 
Fig.1 Effect of study medication on diastolic blood pressure drop standing (a), minimal mean blood pressure 
standing (b), supine systolic peripheral (c) and supine mean central (d) blood pressure, severity of subjective OH 
symptoms (e) and electrolyte levels (f, g). Parkinson´s disease motor symptoms correlated weakly with 
subjective OH symptoms (h). 
 
Table 1 Study population baseline characteristics. 
 
Table 2 Effect of pyridostigmine bromide and fludrocortisone on blood pressure regulation, motor symptoms 
and other autonomic domains in study participants (n=13) 
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Table 1 Study population baseline characteristics 
 
No. Sex/age UPDRSIII ON MoCA LED (mg/d) Diastolic bp drop on 
Schellong (mmHg) 
minimum standing 
mean bp 
OHSA 
1 M / 73 15 26 865 27 67 10 
2 F / 77 17 29 600 15 110 9 
3 M / 78 19 24 1000 10 87 23 
4 M / 65 15 25 600 24 66 9 
5 M / 72 25 26 1165 21 77 11 
6 M / 60 18 29 990 30 58 9 
7 M / 79 45 20 1264 17 65 32 
8 M / 75 22 22 1250 57 32 13 
9 F / 73 23 21 685 15 86 30 
10 M / 66 29 20 1197 39 52 22 
11 M / 67 21 22 550 27 67 24 
12 M / 72 33 20 1412 18 70 17 
13 M / 70 32 27 785 17 81 18 
Mean ± SD 71.3 ± 5.6 24.2 ± 8.6 23.9 ± 3.3 947 ± 295 22.9 ± 13.6 70.7 ± 18.8 17.8 ± 8.4 
Abbreviations: UPDRSIII – United Parkinson`s disease rating scale part III; MoCA - Montreal Cognitive Assessment; LED – levodopa equivalent dose (according to (29));  
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Table 2 Effect of pyridostigmine bromide and fludrocortisone on blood pressure regulation, motor symptoms and other autonomic domains in Parkison`s disease patients with 
symptomatic orthostatic hypotension (n=13) 
 
 
 Baseline 
Pyridostigmin 
bromide 
Fludrocortisone 
Mixed linear repeated 
measures comparison 
LSD post hoc 
comparison 
Peripheral blood pressure on Schellong manoeuvre  
Diastolic bp drop § 
(mmHg)  
22.9 ± 13.6 22.1 ± 17.0 14.0 ± 12.6 p=0.036 ‡ p=0.016 
Systolic bp drop § 
(mmHg) 
41.1 ± 16.9 36.4 ± 11.1 34.6 ± 15.2 p=0.26 n.a. 
Mean systolic bd standing 
∗ (mmHg) 
105.0 ± 16.8  100.2 ± 18.8 112.0 ± 21.8 p=0.34 n.a. 
Mean diastolic bd standing 
∗ (mmHg) 
71.6 ± 1.4 68.6 ±13.9 73.3 ± 15.7 p=0.62 n.a. 
Rate of improvement on 
diastolic bp drop 
n.a. 5/9 (55%) 9/9 (100%) Fisher`s Exact Test p=0.08 n.a. 
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Lowest mean arterial bp 
(MBP) standing § 
(mmHg) 
70.7 ± 18.8 69.9 ± 16.4 83.9 ± 17.3 p=0.038 ‡ p=0.021, © p=0.029 
Systolic bp supine 
(mmHg) 
128.4 ± 12.8 130.4 ± 18.3 143.2 ± 10.1 p=0.012 ‡ p=0.004; © p=0.03 
Diastolic bp supine 
(mmHg) 
79.9 ± 6.7 79.0 ± 9.0 84.6 ± 6.8 p=0.23 n.a. 
Heart rate increase on 
standing § 
10.1 ± 3.1 12.5 ± 4.0 9.2 ± 4.0 p=0.028 # p=0.038; © p=0.011 
Central supine blood pressure  
Central mean bp (mmHg) 107.3 ± 7.8 97.0 ± 12.0 107.3 ± 6.3 p=0.047 # p=0.034; © p=0.029 
Central systolic bp 
(mmHg) 
134.0 ± 14.8 122.7 ± 17.6 137.3 ± 15.3 p=0.16 n.a. 
Central diastolic bp 
(mmHg) 
88.7 ± 6.8 80.8 ± 10.6 89.0 ± 4.3 p=0.056 n.a. 
7d Home bp measurement sitting 
Systolic bp (mmHg) 123.9 ± 16.6 127.7 ± 12.0 139.9 ± 11.0 p=0.002 ‡ p=0.002; © p=0.002 
Diastolic bp (mmHg) 74.6 ± 9.3 74.6 ± 9.8 82.3 ± 9.3 p=0.017  ‡ p= 0.031; © p=0.038 
Heart rate (bpm) 73.0 ± 7.8 69.6 ± 9.3 71.3 ± 6.9 p=0.73 n.a. 
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Overall motor, cognitive and neuropsychiatric functioning and Quality of life 
UPDRSIII 24.2 ± 8.6 24.0 ± 10.5 22.1 ± 10.7 p=0.93 n.a. 
MoCA 23.9 ±3.3 24.1 ± 5.0 25.3 ± 2.7 p=0.61 n.a. 
HADS A 5.1 ± 2.9 4.13 ± 2.7 5.6 ± 5.2 p=0.89 n.a. 
PDQ-39 sum index 24.9 ± 18.6 22.6 ± 12.8 22.3 ± 17.7 p=0.55 n.a. 
Subjective severity of autonomic symptoms 
OHSA 17.8 ± 8.4 16.0 ± 10.8 16.6 ± 14.3 p=0.96 n.a. 
OHDAS 11.5 ± 6.6 10.9 ± 5.0 12.4 ± 10.6 p=0.75 n.a. 
Stool consistency $ 3.2 ± 1.5 1.8 ± 0.9 2.8 ± 1.2 p=0.028  # p=0.015; © =0.07 
Stool frequency per day 0.4 ± 0.7 0.9 ± 0.8 0.9 ± 0.9 p=0.34 n.a. 
Urinary urgency ✝ 3.1 ± 0.9 3.0 ± 0.9 3.5 ± 1.2 p=0.77 n.a. 
Urinary frequency per day 5.3 ± 1.4 6.1 ± 2.2 4.8 ± 2.6 p=0.54 n.a. 
Subjective drooling ✝ 2.2 ± 1.0 2.4 ± 1.3 2.0 ± 1.2 p=0.29 n.a. 
Dizziness on rising ✝ 2.9 ± 0.8 2.4 ± 0.9 2.3 ± 1.0 p=0.14 n.a. 
Electrolytes 
Potassium (mmol/l;  
norm: 3.3 - 4.5) 
3.9 ± 0.29 4.0 ± 0.29 4.0 ± 0.17 p=0.64 n.a. 
Sodium (mmol/l;  
norm: 136 - 145) 
139.7 ± 2.0 136.7 ± 4.1 139.7 ± 2.6 p=0.013 # p=0.009; © p=0.01 
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# baseline vs. Pyridostigmine bromide; ‡ baseline vs. Fludrocortisone; © Pyridostigmine bromide vs. Fludrocortisone; Abbreviations: UPDRSIII – Unified Parkinson`s disease 
rating scale part III; MoCA - Montreal Cognitive Assessment; LED – levodopa equivalent dose (according to (29)); OHSA – Orthostatic Hypotension Severity Assessment; 
OHDAS - Orthostatic Hypotension  Daily Activity Scale; § between 0 and 3 min standing; Zurich Autonomic Questionnaire using a 5 point likert scale from 0 to 5 indicating 
soft to hard ($), respectively little to severe symptom intensity (✝) ; 
 
